- Global Pharma News & Resources

Myasthenia Gravis Treatment Market is geared to grow at a CAGR of 7% from 2023 to 2032, owing to rising adoption of immunotherapies | insightSLICE

The global Myasthenia Gravis Treatment market size was estimated to be US$ 1.2 billion in 2021 and is expected grow at a CAGR of 7% between 2023 to 2032.

The important factors driving the growth of the myasthenia gravis treatment market in the coming years are increased awareness of uncommon illnesses, rising interest in the development of cutting-edge CNS therapeutics, and rising investment in drug discovery.

Drug companies are concentrating on the creation of medications and treatments for use in combination with quick immunotherapies to effectively treat myasthenia gravis.

Access the sample report:

During the projected period, this is expected to stimulate the use of pharmacological therapies for the treatment of myasthenia gravis. The global demand for myasthenia gravis treatments is anticipated to be driven by rising myasthenia gravis occurrences and rising investment in biologics during the projected period.

The key players of the Global Myasthenia Gravis Treatment Market are:

Novartis AG, F. Hoffmann-La Roche AG, Avadel Pharmaceuticals, PLC (Flamel Technologies), Alexion Pharmaceutical Inc., Baxter International, Inc., Shire plc, CSL Behring, Grifols, S.A., Takeda Pharmaceutical Company Limited, and Valeant Pharmaceuticals International, Inc. are major participants in the global myasthenia gravis treatment market.

The global report for myasthenia gravis treatment market:

The Myasthenia Gravis Treatment Market report for the years 2022 to 2032 will cover topics like global market share, trends, and Forecasts. In this report, the years up to 2020 as historic records, the year 2021 serves as the base year and the years from 2022 to 2032 are the forecast period, respectively.

Our research takes into account the competition environment, and the report will include an analysis of the major companies in the worldwide myasthenia gravis therapy market as well as their market forecasts.

In addition, the report will provide information on important advancements, worldwide and regional sales networks, business strategies, research and development initiatives, staff strength, and key executives for all significant market participants.

Read more about the report inclusions:

What is covered in our report?

With an emphasis on every functioning category, the study offers an in-depth analysis of leading companies with a majority share of the worldwide market. It would identify the firm segment that focuses on myasthenia gravis therapy.

Additionally, market shares of well-known businesses in the world market for myasthenia gravis treatments would be calculated. For example, according to Novartis AG’s examination of its product segments, the company’s Innovative Medicines business section generated the majority of the company’s sales in 2019.

They run their operations through two divisions: Innovative Medicines and Sandoz. With a total revenue of US$37,714 million in 2019, the firm’s Innovative Medicines business sector provides myasthenia gravis therapy.

The report also takes into account critical competitive data from all the radial artery compression device manufacturers, including their corporate strategy, product offerings, key developments, SWOT analysis, and research & design emphasis.

The parties involved in the market’s value chain and supply chain, as well as their contributions, will be taken into account in the worldwide research of myasthenia gravis treatments. All of the goods in the company’s myasthenia gravis therapy business sector would be the main focus of the product line segment.

Similarly, the subsection on recent developments will concentrate on the company’s most recent activities, such as competitive partnerships and collaborations, mergers and acquisitions, the introduction of new products, and emerging markets in the industry for myasthenia gravis treatments.

Regional performance of Myasthenia Gravis Treatment Market

Due to the growing number of people with myasthenia gravis, soaring investment in drug discovery, and growing awareness of rare diseases and conditions, North America accounted for the largest share of the global market for myasthenia gravis treatments in 2019 and is expected to continue to hold this position throughout the forecast period.

The market for myasthenia gravis treatments is expected to develop in the near future because of the existence of a strong healthcare infrastructure and fast myasthenia gravis identification and diagnosis.

The market for myasthenia gravis treatments is anticipated to be dominated by Europe. Throughout the projected period, it is predicted that the Asia Pacific myasthenia gravis therapy market would expand steadily.

Related reports:

Global Flow Cytometry Market:

Global Dental Imaging Market:

Global Myasthenia Gravis Treatment Market Key Segments:

By Treatment

  • Medication
  • Surgery
  • Others

By End Use

  • Hospitals
  • Clinics
  • Others

By Geography:

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

Proceed to purchase:

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at

Contact us:

Alex R

+1 707 736 6633

Linkedin | Twitter

Editor Details

Last Updated: 30-Nov-2022